November 22, 2024

Millions in federal funding: customized 3D printing for patients in oral and maxillofacial surgery

Millions in federal funding: customized 3D printing for patients in oral and maxillofacial surgery

The German Federal Ministry of Education and Research (BMBF) is currently funding a project at the Department of Oral and Maxillofacial Surgery at Heidelberg University Hospital (UKHD) with around 1.2 million euros. The aim is to use 3D printing technology to produce individualized implants directly in the clinic, thus enabling faster, more efficient and more precise patient-specific care. To this end, the UKHD is working with an industrial partner.

The ADDIFEM project (Optimized clinical patient care at the point of care through individualized implants using 3D printing technology) aims to significantly improve the care of patients with complex midface fractures and in reconstructive, oncological and malformation-correcting surgery. To this end, state-of-the-art 3D printing technology is being installed to produce individualized implants directly in the clinic. Currently, the time-consuming planning and manufacturing process for such implants significantly extends the time to surgery. “BMBF funding for this model project enables close collaboration between industry and clinics to provide our patients with customized implants faster, more efficiently and more precisely, and to shorten innovation cycles,” says Professor Dr. Dr. Dr. h.c. Jürgen Hoffmann, Medical Director of the Department of Oral and Maxillofacial Surgery at the University Hospital Heidelberg (UKHD).

The project is being carried out by the working group led by Dr. Dr. Reinald Kühle, Senior Physician at the Department of Oral and Maxillofacial Surgery at the UKHD, in close collaboration with the medical technology company KLS Martin SE & Co. KG, and is funded under the BMBF funding guideline “Development of industry-in-clinic platforms for the development of innovative medical products”. For the development phase, the team conducting the first subproject received around 2.2 million euros – in addition to the 1.2 million euros from the BMBF, the industrial partner provided around one million euros. For the three subsequent projects, BMBF funding of up to 4.3 million euros plus industry contributions is planned. The funding period will cover a total of three years.

Step by step towards optimized care

In the first project phase, digital planning and implant design will be increasingly automated and optimized in order to manufacture implants on site on a trial basis in the second phase. The integration of an industrial point of care (PoC), i.e. a permanent presence of the cooperating company KLS Martin SE & Co. KG directly in the clinic, should accelerate and optimize these processes. The aim of the current feasibility study is to establish a new, faster manufacturing process for 3D implants, which should then also be approved outside the UKHD.

“With direct planning and on-site production, we expect not only faster patient care, but also greater precision and accuracy of fit of the customized implants, and thus a higher success rate and a lower risk of complications,” says Dr. Dr. Reinald Kühle. The team also expects that the new manufacturing process will use less material and thus be more efficient and cost-effective than conventional methods, especially when using expensive materials such as PEEK (polyether ether ketone). “It is a great opportunity to develop new materials and processes under clinically relevant conditions and to bring them to production maturity with our partner. This also includes joint training of medical personnel and engineers to achieve the best results,” says Dr. Dr. Kühle.

Our latest News

discover more
RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Heidelberg, Germany, 19.12.2024 – RHEACELL today received approval from the European Medicines Agency (EMA) for its blinded, multi-centric Phase-3 trial (NCT06489028) evaluating allo-APZ2-CVU in patients with chronic venous ulcers (CVU). The pivotal trial will be conducted at more than 100 sites and is expected to enroll 250 patients, starting enrollment in Europe in Q1 2025. […]

Common cough syrup ingredient shows promise in treating serious lung disease

Common cough syrup ingredient shows promise in treating serious lung disease

EMBL scientists discover that an FDA-approved, over-the-counter cough syrup ingredient has potential to treat fibrotic lung disease. Summary A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions.  Scientists from EMBL Heidelberg were part of a […]

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp